Article Sidebar
Views PDF: 119
EVALUATING OVERALL SURVIVAL AT 10 YEARS OF POSTOPERATIVE CHEMORAIDATION THERAPY ON PATIENTS WITH STAGE II, III RECTAL CANCER WAS TREATED AT K HOSPITAL
Main Article Content
Abstract
Purpose: The aims was to evaluate the effectiveness of survival in patients with stage II-III rectal cancer adjuvant given in chemoradiotherapy. Material/methods: From 2012 to 2017, a total of 75 patients with stage II-III rectal cancer at K hospital were evaluated retrospectively for the efficacy of postoperative chemoradiation. Survival data and factors affecting survival were analyzed. Results: Seventy-five patients received postoperative chemoradiotherapy, OS at 10 years was 52.0%. There was a statistically significant difference in overall survival (OS) according to preoperative CEA concentration ≤5 ng/ml was 96,2±6,2 months higher than the group with CEA > 5ng/ml was 54,6±5,8 months, with p=0.01% and median OS after surgery with CEA ≤5 ng/ml after surgery was 85,4±5,6 month higher than the group with CEA > 5ng/ml was 59,1±10,9 months with p =0.2%. OS for stages II and III was 96±6,3 months vs. 59,2±6,0 months. The median OS based on the location of rectal cancer was 86.2±15,5 months, 66.3±5.2 months, and 75.2±5.9 months, respectively (p=0.820). According to the LAR, Miles, and Hartmann procedures, the median OS was 87.4±6.8 months, 74.9±26.9 months, and 41.9±8.1 months, respectively (p=0.035). The median OS for well differentiated (low grade), moderately differentiated (intermediate grade), and poorly differentiated (high grade) cancers was 67.8±10.6 months, 83.76.3 months, and 67.7±9.0 months, respectively (p=0.98). Men had a median OS mean number of 89.0±6.7 months and women had a median OS mean number of 63±6.6 months (p=0.118). Conclusion: Postoperative chemoradiotherapy prolongs survival for patients with stage II-III rectal, there were significant differences in overall survival at 10 years according to CEA concentration before and after surgery, by stage.
Article Details
Keywords
Rectal cancer, Adjuvant therapy, Chemotherapy, Postoperative chemoradiation, Survival
References
2. Nguyễn Văn Hiếu (2010). Ung thư đại trực tràng. Ung thư học, Nhà xuất bản Y học, Hà Nội, 198-213.
3. Sauer R., Liersch T., Merkel S., et al. (2012). Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. JCO, 30(16), 1926–1933.
4. Sauer R., Liersch T., Merkel S., et al. (2012). Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. JCO, 30(16), 1926–1933.
5. Lim Y.J., Kim Y., and Kong M. (2018). Comparative survival analysis of preoperative and postoperative radiotherapy in stage II-III rectal cancer on the basis of long-term population data. Scientific Reports, 8(1), 17153.
6. Hoàng Mạnh Thắng, (2009), Nhận xét đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị ung thư trực tràng giai đoạn T3-T4 tại Bệnh viện K, Luận án tốt nghiệp bác sỹ nội trú, Trường Đại học Y Hà Nội.
7. Arnaud J.P., Koehl C., and Adloff M. (1980). Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum, 23(3), 141–144.
8. Kim J.Y., Kim N.K., Sohn S.K., et al. (2009). Prognostic Value of Postoperative CEA Clearance in Rectal Cancer Patients with High Preoperative CEA Levels. Ann Surg Oncol, 16(10), 2771–2778.
9. Adjuvant Therapy in Rectal Cancer: Analysis of Stage, Sex, and Local Control—Final Report of Intergroup 0114 | Journal of Clinical Oncology. , accessed: 12/20/2020.